Related Blog Posts from the Wikinvest Wire

2013 is considered a landmark year for Haemonetics (HAE) based on several key growth factors, including entry in the $1.2 billion whole blood collection market with the acquisition of the transfusion medicine business of Pall Corp. We are also optimistic about the expected limited market release of the paperless phlebotomy offering by the end of [...]

ViroPharma Inc. (VPHM) recently announced that the European Commission (EC) granted Centralized Marketing Authorization to Cinryze for the treatment of hereditary angioedema (HAE). The drug is indicated for the treatment of pre-procedure prevention of angioedema attacks in adults and adolescents with HAE, and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent [...]

Haemonetics (HAE) will hold its annual investor and analyst day on May 12, 2011 at its corporate headquarters in Braintree, Massachusetts. Other than guidance for fiscal 2012, the company will discuss issues such as the Plasma market scenario, status of IMPACT’s sales and an update on the various R&D initiatives. Haemonetics earns about 82% of its [...]

Haemonetics Corporation (NYSE: HAE) reported 2Q earnings that leads Morgan Keegan to believe that fiscal 3Q is expected to be the low-point in the company's sales cycle. In the report, Morgan Keegan writes "Haemonetics reported fiscal 2Q results that mirrored our expectations with sales that were softer than consensus numbers and EPS that was ahead of expectations. Plasma collections and the pressure on surgical procedures constrained the growth in the 2Q. In our opinion, the 2Q is likely...

Haemonetics Corporation (NYSE: HAE) today reported GAAP net revenues of $166.8 million, up 6%, net income of $21.3 million, up 18%, and earnings per share of $0.85, up 23%. Excluding transformation costs and contingent consideration income in fiscal 11, adjusted second quarter net income was $20.1 million, up 11%, and adjusted earnings per share was $0.80, up 16%. In constant currency, revenue was up 7%, adjusted net income was up 12% and adjusted earnings per share were up 16%. (1) Year...

(TheStreet) -- An analysis of highly-rated large and mid-cap health care stocks by TheStreet Ratings highlights a group of companies with increasing revenue and plenty of growth potential for investors. 10. Haemonetics Corp. Shares of Haemonetics Corp. (NYSE: HAE) of Braintree, Mass. closed at $55.05 Thursday, for a 52-week total return of 3%. It is a medical device company which develops and manufactures automated blood component collection devices and surgical blood salvage devices. Its...

Recently, ViroPharma Inc. (VPHM) announced the initiation of a mid-stage study to evaluate Cinryze (C1 Esterase Inhibitor (Human)) for treating acute angioedema attacks in children (n=12) suffering from hereditary angioedema (HAE). A child has an even probability of being affected with hereditary angioedema if a parent suffers from HAE since it is an autosomal dominant disease. [...]

Haemonetics Corp. (HAE) recently entered a new reagent development and supply agreement with Quotient Biodiagnostics Group and its wholly-owned subsidiary Alba Bioscience Limited. Per the agreement, Haemonetics will have exclusive access to Alba's comprehensive catalogue of approved reagents for use in connection with the commercialization of its Arryx laser based blood typing platform. The agreement includes [...]

Haemonetics Corp. (HAE) recently received the U.S. Food and Drug Administration (FDA) approval for its expanded nomogram to collect two Red Blood Cells on the Cymbal Automated Blood Collection System from female donors. The donors are identified as those who weigh at least 150 pounds and measure 63 inches in height. Cymbal is a battery operated [...]

Haemonetics Corporation (HAE) reported third quarter fiscal 2010 earnings per share of 71 cents, missing the Zacks Consensus Estimate of 72 cents. Earnings in the year-ago quarter were 63 cents. The earnings estimate revision for Haemonetics has demonstrated a downtrend in the past 30 days. During the period, one out of twelve analysts has downgraded his [...]

Haemonetics Corporation (HAE) has recently filed a new lawsuit against Fenwal Inc. regarding the latter’s continued patent infringement with the release of its red cell collection kits. Fenwal allegedly modified its separation chamber to bypass Haemonetics’ patent. The court has issued an injunction prohibiting Fenwal from continuing to sell these infringed products after Dec 1, [...]

Haemonetics Corporation (HAE) reported strong results for the second quarter of fiscal 2010. Earnings per share were 69 cents, beating the Zacks Consensus Estimate of 65 cents and the year-ago earnings of 58 cents. Sales Total revenues in the reported quarter were $157 million, increasing 8% year over year. Excluding a favorable foreign currency translation (FX), revenues [...]

Haemonetics Corp. (HAE) yesterday announced that it has entered into a deal with Blood Centers of America Inc. (“BCA"), a cooperative of community blood centers, which will provide BCA members access to Haemonetics’ blood management software. Specifically, the agreement provides the BCA member’s access to Prelude and Interlude, modules of Haemonetics' integrated Symphony set of [...]

Haemonetics Corporation (HAE) has recently acquired the blood collection and processing business of Engineering and Research Associates Inc., commonly known as SEBRA. The transaction is worth $12.5 million in cash and is expected to be completed in a few months time. The SEBRA acquisition expands the vista of Haemonetics’ product offerings and increases its top-line. Furthermore, [...]